Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.25 Consensus Target Price from Brokerages
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation […]
